Attached files

file filename
8-K - FORM 8-K - K-V Pharmaceutical Cokva20130820_8k.htm

Exhibit 99.1

 

United States Bankruptcy Court

 

  

Southern District of New York

 

  

 

X

  

In re:

:

Chapter 11

 

:

  

K-V Discovery Solutions, Inc. et al.,

:

Case No.  12-13346 (ALG)

 

:

  

Debtors.

X

Jointly Administered

 

 

 

  

 

Monthly Operating Report for the Period

July 1, 2013 to July 31, 2013

 

Debtors’ Address:

16640 Chesterfield Grove Road

  

Suite 200

 

Chesterfield, Missouri 63005

  

Telephone:  (314) 645-6600

  

  

  

Debtors’ Attorneys:

Willkie Farr & Gallagher LLP

  

787 Seventh Avenue

  

New York, New York 10019

  

Telephone:  (212) 728-8000

   

 

This Monthly Operating Report ("MOR") has been prepared solely for the purposes of complying with the monthly reporting requirements applicable in these Chapter 11 cases and is in a format that the Debtors believe is acceptable to the United States Trustee.  The financial information contained herein is limited in scope and covers a limited time period. Moreover, such information is preliminary and unaudited, and is not prepared in accordance with accounting principles generally accepted in the United States ("GAAP").

 

I declare under penalty of perjury that this report and the attached documents are true and correct to the best of my knowledge and belief.

 

 

 

August 15, 2013

Thomas S. McHugh

  

Chief Financial Officer

  

K-V Pharmaceutical Company

 

 

 
 

 

 

 

In re

K-V DISCOVERY SOLUTIONS, INC., et al.,

  

Case No.

12-13346 (ALG)

         
 

Debtors.

  

Reporting Period:

7/1/13 - 7/31/13

         

  

 

  

Federal Tax I.D.#

13-1587982

 

 

CORPORATE MONTHLY OPERATING REPORT

 

File with the Court and submit a copy to the United States Trustee within 20 days after the end of the month and submit a copy of the report to any official committee appointed in the case.

 

(Reports for Rochester and Buffalo Divisions of Western District of New York are due 15 days after the end of the month, as are the reports for Southern District of New York.)

 

REQUIRED DOCUMENTS

Form No.

Document

Attached

Explanation

Attached

Schedule of Cash Receipts and Disbursements

MOR-1

x

 

Bank Reconciliation (or copies of debtor's bank reconciliations)

MOR-1

x

 

     Copies of bank statements

 

 

x

     Cash disbursements journals

 

 

x

Statement of Operations

MOR-2

x

 

Balance Sheet

MOR-3

x

 

Status of Post-petition Taxes

MOR-4

x

x

     Copies of IRS Form 6123 or payment receipt (See Notes to MOR 4)

 

 

x

     Copies of tax returns filed during reporting period (See Notes to MOR 4)

 

 

x

Summary of Unpaid Post-petition Debts (See Notes to MOR 4)

MOR-4

 

x

     Listing of Aged Accounts Payable (See MOR 7)

 

 x

 

Accounts Receivable Reconciliation and Aging

MOR-5

 x

 

Taxes Reconciliation and Aging (See MOR 7)

MOR-5

 

x

Payments to Insiders and Professionals

MOR-6

x

 

Post Petition Status of Secured Notes, Leases Payable

MOR-6

x

 

Debtor Questionnaire

MOR-7

x

 

Makena® Performance Metrics

 

x

 

 

 
- 2 -

 

 

 

NOTES TO MONTHLY OPERATING REPORT

 

This MOR includes activity from the following Debtors:

 

Debtor

Case Number

 

K-V Discovery Solutions, Inc.

12-13346

K-V Pharmaceutical Company

12-13347

Ther-Rx Corporation

12-13348

K-V Generic Pharmaceuticals, Inc.

12-13349

Zeratech Technologies USA, Inc.

12-13350

Drug Tech Corporation

12-13351

K-V Solutions USA, Inc.

12-13352

FP1096, Inc.

12-13353

 

General Notes:

The financial statements and supplemental information contained herein are preliminary, unaudited, and may not comply in all material respects with GAAP.  In addition, the financial statements and supplemental information contained herein represent consolidated information.

 

The unaudited consolidated financial statements have been derived from the books and records of the Debtors and exclude activity for their non-debtor subsidiaries. This information has not been subject to certain procedures that would typically be applied to financial information in accordance with GAAP, and upon application of such procedures the financial information could be subject to changes, and these changes could be material.

 

The financial information contained herein is presented on a preliminary and unaudited basis and remains subject to future adjustment. The Debtors are reviewing their books and records and other information on an ongoing basis to determine whether the financial statements should be supplemented or otherwise amended. The Debtors reserve the right to file, at any time, such supplements or amendments to the financial statements that form a part of this MOR. The financial statements should not be considered an admission regarding any of the Debtors’ income, expenditures or general financial condition, but rather, a current compilation of the Debtors’ books and records. The Debtors do not make, and specifically disclaim, any representation or warranty as to the completeness or accuracy of the information set forth herein.

 

The unaudited consolidated financial statements contained herein have been prepared on a going concern basis and do not reflect or provide all of the possible consequences of the ongoing chapter 11 cases. Specifically, the unaudited consolidated financial statements do not present the amount which will ultimately be paid to settle liabilities and contingencies which may be required in these cases. As a result of the chapter 11 proceedings, the Debtors may take, or may be required to take, actions which may cause assets to be realized, or liabilities to be liquidated, for amounts other than those reflected in the unaudited consolidated financial statements.

  

Certain footnote disclosures normally included in unaudited consolidated financial statements prepared in accordance with GAAP have been condensed or omitted. Preparation of the financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of expenses during the reporting period. The results of operations contained herein are not necessarily indicative of results which may be expected for any other period or for the full year and may not necessarily reflect the consolidated results of operations and financial position of the Debtors in the future.

 

 
- 3 -

 

 

 

MOR-1:

SCHEDULE OF CASH RECEIPTS AND DISBURSEMENTS 1

(Dollars in thousands)

Debtor

 

Case Number

   

Cash Receipts

 

Ther-Rx Corporation

    12-13348     $ 13,235  

DrugTech Corporation

    12-13351       25  

K-V Pharmaceutical Company

    12-13347       8  

K-V Discovery Solutions, Inc

    12-13346       0  

K-V Generic Pharmaceuticals, Inc

    12-13349       0  

Zeratech Technologies USA, Inc

    12-13350       0  

K-V Solutions USA Inc

    12-13352       0  

FP1096, Inc

    12-13353       0  

Total Cash Receipts

    $ 13,268  

 

Debtor

 

Case Number

   

Cash 2

Disbursements

 

K-V Pharmaceutical Company

    12-13347     $ (6,694 )

Ther-Rx Corporation

    12-13348       (6,282 )

DrugTech Corporation

    12-13351       (30 )

K-V Discovery Solutions, Inc

    12-13346       0  

K-V Generic Pharmaceuticals, Inc

    12-13349       0  

Zeratech Technologies USA, Inc

    12-13350       0  

K-V Solutions USA Inc

    12-13352       0  

FP1096, Inc

    12-13353       0  

Total Cash Disbursements

    $ (13,006 )

 

Notes

1 – Cash is received and disbursed by the Debtors as described in the Debtors’ motion to approve continued use of their cash management system (which motion was granted on a final basis pursuant to an order entered by the Bankruptcy Court on January 15, 2013) and is consistent with the Debtors’ historical cash management practices.  All amounts listed are the balances reported by the bank as of the end of the reporting period. Copies of bank statements will be provided upon reasonable request in writing to counsel for the Debtors.

2 – Cash disbursements during the month of July 2013 include $201 of outstanding checks.

 

 

 
- 4 -

 

 

 

MOR-1 (CON’T):

BANK RECONCILIATIONS 1, 2, 3, 4

(Dollars in thousands)

 

Debtor

 

Case Number

 

Bank and Account Description

 

Bank Account No. Ending In

   

Bank Balance

 

K-V Pharmaceutical Company

    12-13347  

Fifth Third Money Market / Investment Account

    1225     $ 30,994  

K-V Pharmaceutical Company

    12-13347  

Fifth Third Bank / Operating Account

    9158       6,419  

K-V Pharmaceutical Company

    12-13347  

Fifth Third Bank / Deposit Account

    0941       2,141  

K-V Pharmaceutical Company

    12-13347  

Fifth Third Bank / Nesher Escrow Account

    0383       501  

K-V Pharmaceutical Company

    12-13347  

Commerce Bank / Certificate of Deposit

    2433       150  

K-V Pharmaceutical Company

    12-13347  

AMEX Centurion Bank / Certificate of Deposit

    8420       60  

Drug Tech Corporation

    12-13351  

Wells Fargo Bank/ DrugTech Operating Acct

    6823       2  

Drug Tech Corporation

    12-13351  

US Bank / DrugTech Custody Account

    3256       2  
                      $ 40,269  

 

Notes

1 –The Debtors have not included copies of their bank statements or cash disbursement journals due to the voluminous nature of these reports. Copies of the Debtors’ bank statements and cash disbursement journals will be provided upon reasonable request in writing to counsel for the Debtors.

2 –The Debtors reconcile their bank accounts on a monthly basis.

3 –The Debtors have excluded accounts with no balance as of the end of the reporting period.

4 –The Debtors’ bank balances exclude $245 of outstanding checks.

  

 

 
- 5 -

 

 

MOR-2:

 

CONSOLIDATED STATEMENT OF OPERATIONS

(Unaudited; Dollars in thousands)

 

 

 

   

For the

Month Ended

July 31, 20131

 

Net revenues

  $ 11,539  

Cost of sales

    124  

Gross profit

    11,415  
         

Research and development

    972  

Selling and administrative

    5,915  

Operating expenses

    6,887  

Operating income

    4,528  
         

Interest, net and other

    872  

Reorganization items, net

    1,829  

Total other expense

    2,701  
         

Income from continuing operations before income taxes

    1,827  

Income tax provision

    1,081  

Net income from continuing operations

  $ 746  

 

Notes

1 – The Debtors prepare their income statement on an accrual basis. Accordingly, the Debtors’ Statement of Operations, as set forth in this MOR, reflects the results of the Debtors’ operations for the month of July 2013.

 

 

 
- 6 -

 

 

 

MOR-3:

CONSOLIDATED BALANCE SHEET

(Unaudited; Dollars in thousands)

 

   

 

 
   

As of

July 31, 2013

 

ASSETS

       

Current Assets:

       

Cash and cash equivalents

    39,311  

Restricted cash

    561  

Undrawn DIP Facility proceeds

    21,950  

Receivables, net

    24,792  

Inventories, net

    6,821  

Other current assets

    2,862  

Total Current Assets

    96,297  

Property and equipment, less accumulated depreciation

    1,253  

Intangible assets, net

    104,576  

Other assets

    15,110  

Total Assets

  $ 217,236  
         

LIABILITIES

       

LIABILITIES NOT SUBJECT TO COMPROMISE:

       

Current Liabilities:

       

Accounts payable

  $ 5,786  

Accrued expenses

    34,320  

Other current liabilities

    501  

Debtor-in-Possession Financing 1

    86,612  

Total Current Liabilities

    127,219  

Other long-term liabilities

    62  

Total Liabilities not subject to compromise

    127,281  

Total liabilities subject to compromise

    585,276  

Total Liabilities

    712,557  
         

SHAREHOLDERS' DEFICIT

       

Preferred Stock

 

 

Class A Common Stock

    660  

Class B Common Stock

    96  

Additional paid-in capital

    206,515  

Accumulated deficit

    (645,183 )

Less: Treasury stock

    (57,409 )

Total Shareholders' Deficit

    (495,321 )

Total Liabilities and Shareholders' Deficit

  $ 217,236  

 

Notes

1 – Debtor-in-Possession Financing includes the amount of $85,000 under the Debtors’ debtor-in-possession financing facility (the “DIP Facility”), which was approved pursuant to an order of the Bankruptcy Court (the “DIP Order”) entered on December 27, 2012 [Docket No. 497], as well as accrued paid-in-kind interest of $1,612. For administrative purposes, the unused proceeds of the DIP Facility are being held in an account in the name of Silver Point Finance, LLC, the agent for the DIP Facility.

 

 
- 7 -

 

 

MOR-4:

 

STATUS OF POST-PETITION TAXES 1, 2

(Dollars in thousands)

 

Federal

 

Beginning Tax

   

Amount Withheld and/or Accrued

   

Amount Paid

   

Ending Tax

 

Withholding

  $ 0     $ 186     $ (186 )   $ 0  

FICA-Employee

    0       70       (70 )     0  

FICA-Employer

    0       70       (70 )     0  

Total Federal Taxes

  $ 0     $ 326     $ (326 )   $ 0  
                                 

State and Local

                               

Withholding

  $ 0     $ 52     $ (52 )   $ 0  

Sales Tax

    2       0       0       2  

Unemployment Tax

    0       0       0       0  

Real Property

    13       0       0       13  

Personal Property

    24       1       0       25  

Franchise Tax

    7       18       (60 )     (35 )

Total State and Local

  $ 46     $ 71     $ (112 )   $ 5  
                                 

Total Taxes

  $ 46     $ 397     $ (438 )   $ 5  

 

 

Notes

1 - The Debtors have not annexed copies of tax returns filed with various taxing authorities during the current reporting period to this MOR, nor have they included the Debtors’ IRS Form 6123 with this MOR. Copies of such tax returns and IRS Form 6123 will be provided upon reasonable request in writing to counsel for the Debtors.

2 - The Debtors believe they are paying all undisputed taxes and preparing and filing all tax returns when due or obtaining extensions where necessary.

 

 

 
- 8 -

 

 

 

MOR-4 (CON’T):

SUMMARY OF UNPAID POST-PETITION DEBTS 1

(Dollars in thousands)

 

 

 

Description

 

Amount

 
         

0 - 30 days old

  $ 2,288  
         

31+ days old

    3,498  
         

Total Vendor Accounts Payable Post-petition

  $ 5,786  

 

Notes

1 - The Debtors believe they are paying all undisputed post-petition obligations according to terms.  

 

 

 
- 9 -

 

 

 

MOR-5:

ACCOUNTS RECEIVABLE RECONCILIATION AND AGING

(Dollars in thousands)

 

 

Description

 

Amount

 

0 - 30 days old

  $ 26,209  
         

31 - 60 days old

    51  
         

61 - 90 days old

    (69 )
         

91+ days old

    1,013  
         

Total Customer Accounts Receivable

  $ 27,204  
         

Customer Allowances

    (2,412 )
         

Total Accounts Receivable

  $ 24,792  

  

 

 
- 10 -

 

 

 

MOR-6:

PAYMENTS TO INSIDERS AND PROFESSIONALS

(Dollars in thousands)

 

INSIDERS

 

Name

Type of Payment 1

 

Current Month

Amount Paid

   

Total Paid Since

August 4, 2012 2

 

Christmas, Patrick

Salary/Expenses

  $ 19     $ 247  

Divis, Gregory

Salary/Expenses

    29       362  

McHugh, Thomas

Salary/Expenses

    18       241  

Stancic, Ana

Director Fees/Expenses

    54       180  

Hermelin, David

Director Fees/Expenses

    57       190  

Sidransky M.D., David

Director Fees/Expenses

    55       184  

Bentley, Greg

Director Fees/Expenses

    53       176  

Lehrer, Joe

Director Fees/Expenses

    74       248  

Dow, Mark

Director Fees/Expenses

    62       208  

Baldini, Robert

Director Fees/Expenses

    54       180  

Total

  $ 475     $ 2,216  

 

Notes

1 – Additional detail concerning payments to the Debtors’ insiders will be provided upon reasonable request in writing to counsel for the Debtors.

 

 
- 11 -

 

 

 

MOR-6 (CONT):

 

PROFESSIONALS 1

 
   

Name

Date of Court

Order

Authorizing

Payment

 

Amount

Requested 2

   

Current

Month

Amount Paid

   

Total Paid

To Date 3

   

Total

Invoiced &

Unpaid

 

Alston & Bird LLP

14-Sep-12

  $ 21     $ 0     $ 393     $ 21  

Arnall Golden Gregory LLP

10-Oct-12

    2       2       61       15  

Brown Rudnick LLP 5

07-Jun-13

    24       0       109       24  

Curtis, Mallet-Prevost, Colt & Mosle LLP

15-Jan-13

    0       13       174       84  

Dechert LLP 5

07-Jun-13

    0       0       1,059       0  

Duff & Phelps, LLC

10-Oct-12

    115       92       922       225  

Epiq Bankruptcy Solutions, LLC

27-Sep-12

    49       39       326       25  

Ernst & Young, LLP

28-Sep-12

    0       33       105       26  

Fortgang Consulting

14-Sep-12

    0       0       301       0  

FourSquare Partners

5-Apr-13

    13       13       88       0  

Houlihan & Lokey Capital, Inc.

14-Sep-12

    150       302       1,998       0  

Jefferies & Company, Inc.

10-Oct-12

    0       0       1,883       190  

Lowenstein Sandler PC 4,5

27-Dec-12

    0       0       1,585       0  

Riker, Danzig, Scherer, Hyland, Perretti LLP 5

07-Jun-13

    0       0       31       0  

Sidley Austin LLP5

07-Jun-13

    0       0       741       0  

Stroock Stroock & Lavan LLP

10-Oct-12

    423       0       2,833       1,478  

Weil, Gotshal & Manges LLP

27-Sep-12

    0       958       4,771       0  

White & Case LLP 5

07-Jun-13

    0       0       741       0  

Willkie Farr & Gallagher LLP

27-Sep-12

    486       697       5,932       1,921  

Total

    $ 1,295     $ 2,149     $ 24,053     $ 4,021  

 

Notes

1 – Represents professional services exclusive of those rendered by professionals retained by the Debtors pursuant to the September 27, 2012 order of the Bankruptcy Court authorizing the Debtors to employ and retain professionals utilized in the ordinary course of business.

2 – Represents amounts requested during the current reporting period.

3 – Represents payments made from the date of the Bankruptcy Court’s order authorizing each firm’s retention.

4 – Of the total fees paid to date, $400 represents a payment made pursuant to the DIP Order.

5 – Represents fees authorized to be paid as set forth on the record of the hearing held on June 7, 2013 [Docket 937]; see also Order: (A) Authorizing Debtors To Enter Into And Satisfy Obligations Under Share Purchase Agreement; (B) So Ordering Record Of June 7, 2013 Hearing; And (C) Granting Related Relief [Docket No. 962].

 

 
- 12 -

 

 

 

MOR-6 (CON’T):

 

POST-PETITION STATUS OF SECURED NOTES, LEASES PAYABLE

AND ADEQUATE PROTECTION PAYMENTS 1

(Dollars in thousands)

 

Name of Creditor

 

Scheduled Monthly

Payment Due

   

Amount Paid

During Month

 

Building lease payable2

  $ 19     $ 19  
                 
   

Total Payments

    $ 19  

 

Notes

1 - The Debtors’ schedule of lease payments, as set forth in this MOR, only reflects payments made pursuant to the Debtors’ real property leases. Immaterial leases of personal property are not included in this MOR-6.

2 – On February 13, 2013, the Bankruptcy Court entered an order authorizing the Debtors to enter into a new corporate headquarters lease agreement for premises located at 16640 Chesterfield Grove Road, Suite 200, Chesterfield, Missouri [Docket No. 598].

 

 
- 13 -

 

 

 

MOR-7:

DEBTOR QUESTIONNAIRE

 

Must be completed each month.  If the answer to any of the questions is "Yes", provide a detailed explanation of each item.  Attach additional sheets if necessary.

Yes

No

  

 

  

  

  

1

 

Have any assets been sold or transferred outside the normal course of business this reporting period?

 

X

2

 

Have any funds been disbursed from any account other than a debtor in possession account this reporting period?

 

X

3

 

Is the Debtor delinquent in the timely filing of any post-petition tax returns?

  

X

4

 

Are workers compensation, general liability or other necessary insurance coverages expired or cancelled, or has the debtor received notice of expiration or cancellation of such policies?

  

X

5

 

Is the Debtor delinquent in paying any insurance premium payment?

  

X

6

 

Have any payments been made on pre-petition liabilities this reporting period?

X

  

7

 

Are any post-petition receivables (accounts, notes or loans) due from related parties?

  

X

8

 

Are any post-petition payroll taxes past due?

  

X

9

 

Are any post-petition State or Federal income taxes past due?

  

X

10

 

Are any post-petition real estate taxes past due?

  

X

11

 

Are any other post-petition taxes past due?

  

X

12

 

Have any pre-petition taxes been paid during this reporting period?

 

X

13

 

Are any amounts owed to post-petition creditors delinquent?

  

X

14

 

Are any wages payments past due?

  

X

15

 

Have any post-petition loans been received by the Debtor from any party?

 

X

16

 

Is the Debtor delinquent in paying any US Trustee fees?

  

X

17

 

Is the Debtor delinquent with any court ordered payments to attorneys or other professionals?

  

X

18

 

Have the owners or shareholders received any compensation outside of the normal course of business?

  

X

 

Explanations

 

6

Pursuant to an order entered by the Bankruptcy Court, the Debtors were authorized to pay certain pre-petition customer obligations [Docket Nos. 85 & 338]. 

 

13

The Debtors believe that all undisputed post-petition accounts payable have been and are being paid according to agreed-upon terms specific to each vendor and/or service provider.  Any aged amounts represent items subject to valid disputes and certain items which have been paid subsequent to the end of this reporting period.       

 

 

 
- 14 -

 

 

Makena® Performance Metrics

Makena® (hydroxyprogesterone caproate injection) is the Debtors’ single-most valuable product. The information below addresses certain key performance metrics related to Makena®. The amounts shown are based on estimates and are subject to change. Gross revenues are preliminary and unaudited, and are not prepared in accordance with GAAP.

 

Three Months Ended

 

Gross Revenues

($ in thousands)(1)

   

Total Prescriptions (2)

   

Vials Shipped to Customers (3)

 

12/31/2012

  $ 23,495       3,452       6,810  

3/31/2013

  $ 29,014       4,302       8,410  

6/30/2013

  $ 38,009       4,821       11,017  

7/31/2013(4)

  $ 41,507       4,715       12,031  

 

Notes:

     

(1) Amounts shown are estimated based on the number of vials shipped to customers and list price/vial.

 

(2) Represents total prescriptions reported to the Debtors.

 

(3) Represents paid vials shipped to the Debtors' customers, which include specialty pharmacies and distributors.

 

(4) Data for the months of May 2013, June 2013, and July 2013 is used in the absence of complete data for the three months ending September 30, 2013.


- 15 -